📰 Plus Chemo News
Plus Chemo News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Plus Chemo. Real-time updates on events, politics, business and more.
January 25, 2024
Neither atezolizumab plus chemotherapy nor atezolizumab alone improved overall survival when compared to chemotherapy alone in patients with advanced urothelial cancer in the phase 3 IMvigor130 trial. Neither atezolizumab plus chemotherapy nor atezolizumab alone improved OS when compared to chemotherapy alone in patients with advanced urothelial cancer.
January 17, 2024
Neither atezolizumab plus chemotherapy nor atezolizumab alone improved overall survival when compared to chemotherapy alone in patients with advanced urothelial cancer in the phase 3 IMvigor130 trial. Neither atezolizumab plus chemotherapy nor atezolizumab alone improved OS when compared to chemotherapy alone in patients with advanced urothelial cancer.
January 11, 2024
Neither atezolizumab plus chemotherapy nor atezolizumab alone improved overall survival when compared to chemotherapy alone in patients with advanced urothelial cancer in the phase 3 IMvigor130 trial. Neither atezolizumab plus chemotherapy nor atezolizumab alone improved OS when compared to chemotherapy alone in patients with advanced urothelial cancer.
October 16, 2023
16.10.2023 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of promising new data showcasing BeiGene’s robust, science-driven solid tumor portfolio of commercialized and pipeline medicines ... Seite 1